FLT3L-secreting cDC1 in situ vaccination enhances antitumor immunity and synergizes with PD-1 blockade in murine non-small cell lung cancer - PubMed
3 hours ago
- #In Situ Vaccination
- #Dendritic Cell Therapy
- #Immune Checkpoint Blockade
- FLT3L-secreting cDC1 in situ vaccination (ISV) enhances antitumor immunity and synergizes with PD-1 blockade in murine non-small cell lung cancer (NSCLC) models.
- FLT3L-cDC1 ISV remodels the tumor microenvironment, inducing T lymphocyte infiltration, expanding cytolytic CD8+ T cells, and promoting immature tertiary lymphoid structure (TLS) formation.
- TCGA analyses show FLT3L expression correlates with activated dendritic cell, T cell, and B cell signatures, as well as high endothelial venule-enriched TLS programs.
- Combination with PD-1 blockade further enhances immunity, activating local/systemic T cells and expanding CCR7+PD-L1+ cDC1s and stem-like TCF1+PD-1+ CD8+ progenitors.
- In an LKB1-deficient NSCLC model, FLT3L-cDC1 ISV plus PD-1 blockade induces complete and durable regression in 85% of tumors and establishes long-lasting tumor-specific immune memory.